Protagonist Therapeutics
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical enterprise headquartered in Newark, California. The company focuses on the discovery, development, and commercialization of novel peptide-based therapeutics designed to target complex hematological, inflammatory, and rare diseases. Its proprietary technology platform enables the creation of oral and injectable peptide drugs addressing unmet medical needs. Principal revenue is earned through pharmaceutical research collaboration agreements, clinical milestone payments, and co-development partnerships. The enterprise serves specialized clinical researchers and healthcare systems. Protagonist Therapeutics Inc is publicly traded on the Nasdaq Stock Market.
9 of the funds FundTelligence covers report a position in Protagonist Therapeutics.
- Legal name
- Protagonist Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 9
Funds holding Protagonist Therapeutics
- SEB Läkemedelsfond — SEB · 1.43 % (full portfolio disclosed, June 2026)
- BNP US Small Cap — BNP Paribas · 0.82 % (full portfolio disclosed, June 2026)
- BNP Health Care Innovators — BNP Paribas · 0.63 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.55 % (full portfolio disclosed, October 2026)
- Nordea BetaPlus Enhanced Global Sustainable Small Cap — Nordea Funds · 0.33 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.09 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.06 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.06 % (partially disclosed portfolio, June 2026)
Showing the 8 largest of 9 funds holding it.